Articles

Chemotherapy plus immunotherapy (IO) may improve efficacy outcomes over IO alone in most patients with advanced non–small-cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) scores between 1% and 49%. Read More ›

On October 8, 2020, the Berkeley Research Group published a report showing that contract pharmacy participation in the 340B Drug Pricing Program grew by 4228% between 2010, when the Health Resources and Services Administration expanded the contract pharmacy program, and 2020. A week later, on October 16, 2020, a variety of stakeholders in the 340B program—covered entities, contract pharmacies, pharmaceutical manufacturers, and outside tech consultants—participated in an intense discussion of contract pharmacy growth, newly imposed manufacturer audit requirements, and ways to return 340B to its original purpose of spreading scarce federal resources and serving vulnerable patients. Read More ›

After Medicare, employers are the largest purchasing group in cancer care. In this session, experts offer employers’ perspectives on health benefit plans, as well as issues that frequently arise when designing plans, managing costs, and defining value. Read More ›

Value-based contracts (VBCs) are the future of healthcare. However, many barriers to entry exist for the exploration of these contracts. In this discussion, experts offer legal perspectives on the goals of VBCs and potential hurdles and solutions. Read More ›

As the COVID-19 pandemic continues, patients with cancer face numerous challenges. Healthcare professionals continue to play a critical role in advocating for their patients’ access to care. Read More ›

In recent years, there has been an increase in the number of innovative treatments developed for the management of patients with cancer, including CAR T-cell therapies. In this session, experts from all facets of healthcare offered their perspectives on the use of these agents in the context of value-based care. Read More ›

Virtual care, which has existed in the background of medicine for years, has now come to the forefront during the COVID-19 pandemic. Experts on telehealth weighed in on the impact of this technology on cancer care and what is on the horizon. Read More ›

In this session, a panel of experts from all branches of healthcare make predictions on the cancer care forecast post-election. Read More ›

The current climate of COVID-19 and political uncertainty has made an impact on the future of cancer care. Top CEOs give their perspective on what lies ahead. Read More ›

In this session, expert panelists discuss the impact of COVID-19, future trends in access and management, and upcoming trends in oncology. Read More ›